These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 31442016)

  • 1. COTA collaboration: helping FDA figure out what's possible, what's not in embrace of real-world evidence.
    Norden A; Caffrey M
    Am J Manag Care; 2019 Aug; 25(9 Spec No.):SP266-SP268. PubMed ID: 31442016
    [No Abstract]   [Full Text] [Related]  

  • 2. Evidence based medicine: what's new--what's not--what's needed.
    Goethe JW
    Conn Med; 2003; 67(10):637-8. PubMed ID: 14677344
    [No Abstract]   [Full Text] [Related]  

  • 3. ISPOR, the FDA, and the Evolving Regulatory Science of Medical Device Products.
    O'Neill T; Miksad R; Miller D; Maloney L; John A; Hiller C; Hornberger J
    Value Health; 2019 Jul; 22(7):754-761. PubMed ID: 31277820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What's Needed to Bridge the Gap Between US FDA Clearance and Real-world Use of AI Algorithms.
    Lin M
    Acad Radiol; 2022 Apr; 29(4):567-568. PubMed ID: 34794879
    [No Abstract]   [Full Text] [Related]  

  • 5. What's usable and what's missing in evidence-based medicine for fracture management.
    Helfet DL; Hanson BP
    Am J Orthop (Belle Mead NJ); 2011 Sep; 40(9):450-1. PubMed ID: 22022673
    [No Abstract]   [Full Text] [Related]  

  • 6. Public-Private Partnership: Targeting Real-World Data for Hepatitis C Direct-Acting Antivirals.
    Mishra P; Florian J; Peter J; Vainorius M; Fried MW; Nelson DR; Birnkrant D
    Gastroenterology; 2017 Sep; 153(3):626-631. PubMed ID: 28757271
    [No Abstract]   [Full Text] [Related]  

  • 7. OTCs under review: an update on what's in and what's out.
    Welsh JS
    Am Pharm; 1980 Sep; NS20(9):11-5. PubMed ID: 7424784
    [No Abstract]   [Full Text] [Related]  

  • 8. What's with the FDA?
    Rapaport HG
    Ann Allergy; 1973 Oct; 31(10):515. PubMed ID: 4768548
    [No Abstract]   [Full Text] [Related]  

  • 9. To have (medical devices) or not: what's safer for patients?
    McCormack J
    Health Facil Manage; 1995 Jun; 8(6):44, 46, 48. PubMed ID: 10142630
    [No Abstract]   [Full Text] [Related]  

  • 10. Public-private partnerships: what's in the public interest?
    Stauffer M
    Behav Healthc Tomorrow; 1996 Apr; 5(2):19-20. PubMed ID: 10157571
    [No Abstract]   [Full Text] [Related]  

  • 11. Twelve partnerships. What's it all about?
    Behav Healthc Tomorrow; 1997 Apr; 6(2):73-4. PubMed ID: 10166632
    [No Abstract]   [Full Text] [Related]  

  • 12. FDA, Gottlieb Get Real About Real-world evidence.
    Kirkner RM
    Manag Care; 2019 Mar; 28(3):13-16. PubMed ID: 30883304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topotecan: after FDA and ASCO, what's next?
    McNeil C
    J Natl Cancer Inst; 1996 Jun; 88(12):788-9. PubMed ID: 8637042
    [No Abstract]   [Full Text] [Related]  

  • 14. EBM (evidence-based medicine): what's new and what's on the Net.
    Med Manag Netw; 1998 Apr; 6(4):8-10. PubMed ID: 10182970
    [No Abstract]   [Full Text] [Related]  

  • 15. From the FDA: what's in a label? A guide for the anesthesia practitioner.
    Chang NS; Simone AF; Schultheis LW
    Anesthesiology; 2005 Jul; 103(1):179-85. PubMed ID: 15983471
    [No Abstract]   [Full Text] [Related]  

  • 16. The clinical research enterprise in critical care: what's right, what's wrong, and what's ahead?
    Reade MC; Angus DC
    Crit Care Med; 2009 Jan; 37(1 Suppl):S1-9. PubMed ID: 19104206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What's new about evidence-based assessment?
    Barlow DH
    Psychol Assess; 2005 Sep; 17(3):308-11. PubMed ID: 16262456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What’s in a name? HRSA and the FDA consider adding vascularized composite allografts to their definition of "organs".
    Pondrom S
    Am J Transplant; 2010 Sep; 10(9):1953. PubMed ID: 20887424
    [No Abstract]   [Full Text] [Related]  

  • 19. The PCAST report on pharmaceutical innovation: implications for the FDA.
    Woodcock J
    Clin Pharmacol Ther; 2013 Sep; 94(3):297-300. PubMed ID: 23963215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catalyzing the Critical Path Initiative: FDA's progress in drug development activities.
    Parekh A; Buckman-Garner S; McCune S; ONeill R; Geanacopoulos M; Amur S; Clingman C; Barratt R; Rocca M; Hills I; Woodcock J
    Clin Pharmacol Ther; 2015 Mar; 97(3):221-33. PubMed ID: 25670629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.